ArticleEuropean radiology2026
Diagnostic accuracy of MDCT for preoperative peritoneal cancer index estimation in advanced ovarian cancer undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC): a Sugarbaker-based analysis.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesIntegration of hyperthermic intraperitoneal chemotherapy (HIPEC) into interval cytoreductive surgery (CRS) has improved recurrence-free and overall survival in patients with advanced ovarian cancer. Multidetector computed tomography (MDCT) is routinely used for preoperative evaluation via the peritoneal cancer index (PCI). This study aimed to assess the diagnostic accuracy of MDCT in predicting intraoperative PCI. MATERIALS AND
methodsThis retrospective, single-center study analyzed 69 patients with advanced ovarian cancer who underwent MDCT within 90 days prior to CRS with HIPEC between April 2014 and April 2023. Peritoneal lesions were scored using the Sugarbaker system across 13 regions, assigning lesion size (LS) scores from 0 to 3. MDCT-derived PCI was compared with intraoperative PCI. Diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated.
resultsPeritoneal deposits were identified in 382 out of 897 regions (42.6%) during surgery. MDCT achieved 60.7% sensitivity and 91.3% specificity for differentiating LS 0-1 vs. 2-3, and 52.1% sensitivity and 87.4% specificity for LS 0 vs. 1-3. Overall accuracy was 84.1% and 72.4% for these respective thresholds. A strong correlation was observed between MDCT-PCI (7.3 ± 6.1) and intraoperative PCI (9.8 ± 6.9) (r = 0.83, p < 0.05). Optimal cytoreduction was achieved in 94% of patients.
conclusionMDCT reliably estimates peritoneal cancer index and guides surgical planning in HIPEC candidates with extensive disease, but its sensitivity for small or subcentimeter lesions, especially in the small bowel, remains limited, necessitating adjunctive imaging modalities. KEY POINTS: Question Can contrast-enhanced multidetector CT accurately estimate the Sugarbaker peritoneal cancer index preoperatively to guide surgical selection in advanced ovarian cancer undergoing HIPEC? Findings Dual-threshold MDCT analysis demonstrated a strong correlation with intraoperative PCI (r = 0.83) and achieved 84.1% accuracy for identifying clinically significant peritoneal disease. Clinical relevance Preoperative MDCT-based PCI assessment supports surgical planning and prognostic stratification in advanced ovarian cancer considered for HIPEC. Although sensitivity is limited for small bowel lesions, MDCT provides clinically useful tumor burden estimation to guide treatment selection.
Indexed as
Identifiers
41995741What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.